GLP-1 Weight-Loss Drugs Explained: Benefits, Risks and Why Medical Supervision Matters

Agencies- Health News, April 12, 2026 :  The rapid rise in the use of GLP-1 (Glucagon-Like Peptide-1)  receptor agonists for weight loss across India is drawing increasing concern from medical professionals, as more individuals turn to these powerful drugs without proper supervision, often with unintended and potentially harmful consequences.

GLP-1 is a naturally occurring hormone in the body that plays a key role in regulating blood sugar and appetite. It is released from the gut after eating and helps to stimulate insulin secretion, slow down digestion, and signal the brain to feel full.

GLP-1 receptor agonists are medications designed to mimic this hormone. They are used primarily to treat type 2 diabetes and, more recently, for weight management. By reducing hunger and increasing satiety, these drugs help people eat less and lose weight. Common examples include semaglutide and tirzepatide, which have gained global attention for their effectiveness. However, while these medications can be highly beneficial when prescribed and monitored by doctors, unsupervised use can lead to serious health risks such as muscle loss, nutritional deficiencies, and metabolic complications.

Dr Gagandeep Singh recounts a recent case that reflects a growing trend. A patient who visited his clinic had lost eleven kilograms in just six weeks. While the weight loss appeared dramatic, her overall health had deteriorated—her muscle mass had significantly reduced, her hair was thinning, and her blood reports indicated early signs of nutritional deficiencies. She had been self-administering a GLP-1 receptor agonist, obtained through an Instagram contact, without any medical guidance. Such cases, he notes, are no longer rare but increasingly common.

The popularity of these drugs is not without reason. GLP-1 receptor agonists such as semaglutide and tirzepatide, globally marketed as Ozempic, Wegovy and Mounjaro, represent a major advancement in pharmacology. Clinical trials like STEP have demonstrated average weight loss of 15–17 per cent of body weight, while the SELECT trial has shown cardiovascular benefits even in individuals without diabetes. Their scientific foundation is strong, and their therapeutic potential is well established. However, effectiveness under clinical supervision does not translate into safety when these medications are used without medical oversight.

In many urban areas across India, access to these injections has expanded beyond clinics into informal networks, including social media and messaging platforms. Individuals are increasingly relying on advice from influencers or online communities, adjusting doses on their own and drastically reducing food intake due to the appetite-suppressing effects of the drugs. This pattern of use creates serious health risks.

GLP-1 agonists significantly reduce hunger, and without structured nutritional planning, patients often consume inadequate and imbalanced diets. In some cases, daily caloric intake drops to as little as 600 to 800 calories, consisting largely of nutritionally poor foods. Under such conditions, the body does not selectively burn fat; instead, it begins to break down muscle tissue. This leads to what researchers describe as “muscle wasting with weight loss,” where a substantial portion of weight loss comes from lean body mass rather than fat.

This issue is particularly concerning in the Indian context. Many Indians naturally have lower muscle mass compared to Western populations, making them more vulnerable to the adverse effects of muscle loss. As a result, individuals may appear thinner but become metabolically weaker, increasing long-term health risks rather than reducing them.

India’s unique metabolic profile further complicates the situation. Insulin resistance is often observed at lower body weights compared to global standards. For instance, an individual with a seemingly normal body weight may still have high metabolic risk indicators. When such individuals lose muscle mass through unsupervised use of GLP-1 drugs, they may develop what is commonly referred to as the “skinny-fat” phenotype—low body weight accompanied by high metabolic risk. This outcome runs counter to the intended benefits of these medications.

When prescribed and monitored by healthcare professionals, the use of GLP-1 drugs follows a very different approach. Physicians track not just weight but also body composition, ensuring that muscle mass is preserved. Nutritional plans emphasise adequate protein intake, and resistance training is often recommended to counter muscle loss. Micronutrient levels are regularly assessed, and dosages are carefully adjusted based on individual responses.

Equally important is long-term planning. Medical supervision addresses a critical question often overlooked in self-medication: what happens after the drug is discontinued. Without sustainable changes in diet and lifestyle, weight regain is common, and it often returns as fat rather than muscle. This can leave individuals more insulin resistant and metabolically compromised than before starting treatment.

Dr Singh emphasises that the concern is not with the drugs themselves. When used appropriately, GLP-1 medications can be highly effective and serve as a valuable tool in managing weight and metabolic health. However, the issue arises when these prescription medications are treated as easily accessible consumer products, without regard for their side effects, nutritional implications or long-term impact.

Weight loss alone does not equate to improved health. Losing significant weight while compromising muscle mass, bone density and nutritional status can result in a different set of health problems. The visible outcome may appear positive, but the underlying damage can be substantial.

The increasing trend of self-administered weight-loss injections in India is therefore not merely a passing fad but a growing public health concern. As awareness spreads and more individuals seek quick results, the risks associated with unsupervised use are likely to become more evident. Medical experts caution that without proper guidance, what appears to be a solution today may lead to more complex health challenges in the future.